Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc. has demonstrated a positive trajectory, evidenced by the stock's significant rise during the third quarter and the ongoing advancement of its pipeline, including four active Phase 3 trials. The company reported a substantial increase in R&D expenses, indicative of investment in its innovative product candidates, including tarcocimab, which has shown promising initial results in improving visual acuity in patients. Furthermore, encouraging feedback from retinal key opinion leaders (KOLs) and the successful achievement of pivotal trial endpoints strengthen the outlook for the company's lead assets, bolstering confidence in the potential for future growth and successful product approvals.

Bears say

Kodiak Sciences Inc. faces significant risks that could hinder its financial performance, including the potential failure of its developmental candidates, particularly Tarcocimab, to meet peak commercial revenue estimates due to factors like market size and pricing strategies. The need for substantial capital resources to support operations and the establishment of a global sales infrastructure could lead to increased cash burn, which may be perceived negatively by investors. Moreover, the inconsistencies in efficacy observed in clinical trials and potential regulatory delays for its pipeline products further exacerbate the uncertainty surrounding the company's future financial outlook.

KOD has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 6 analysts, KOD has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.